At-Home Heart Failure Therapy Showed Promise in Trial
A new device for managing fluid buildup allowed patients to treat symptoms at home with high success rates in a recent study.
Updated on Oct. 11, 2026 in Heart Disease
Live Poll
Would you prefer using home-based medical devices over traditional hospital visits for managing chronic conditions?
Early results from the Gator SCALES-WHF trial suggest that a subcutaneous furosemide delivery device may help patients manage heart failure volume overload at home. The findings, which may offer an alternative to traditional hospital-based treatment for patients with heart failure, were presented at the HFSA Annual Scientific Meeting 2026.
Why it matters
Clinicians are investigating ways to provide sustainable, escalated therapy for patients who have failed oral diuretic titration and struggle with volume overload. This approach aims to reduce the burden of hospital visits for patients requiring consistent diuretic management.
This preliminary report from the Gator SCALES-WHF trial evaluated 21 patients with a mean age of 63.1 years, 67% of whom had heart failure with reduced ejection fraction. While 91% of subcutaneous furosemide applications were successful, the trial remains ongoing with a target of 100 participants.
The players
University of Florida
The academic institution overseeing the research and the primary affiliation of the lead investigators.
HFSA Annual Scientific Meeting 2026
The professional forum where these preliminary trial findings were first presented to the medical community.
The details
The device uses subcutaneous delivery to administer furosemide, a loop diuretic that helps the body remove excess sodium and water. Patients receive the device and refill cartridges during a clinic visit to enable at-home decongestion under standard-of-care lab monitoring. By providing a method for escalated diuretic therapy outside of a clinical setting, researchers hope to manage patients with volume overload more effectively.
Timeline
October 9-12, 2026: Results were presented at the HFSA Annual Scientific Meeting 2026.
Day 3: No patients required hospitalization or emergency visits.
Day 7: One patient was admitted to the hospital following an emergency room visit.
Day 20: Three total patients had been admitted to the hospital.
30 days: This period marks the full primary outcome safety assessment for participants.
Health Landscape
The Gator SCALES-WHF clinical trial is currently evaluating new methods for managing heart failure volume overload, marking a departure from traditional inpatient-only escalation protocols. This study aligns with a broader research trend seeking to move intensive heart failure care from the hospital to the home.
If you are managing heart failure, these findings underscore the importance of discussing current symptom management and volume monitoring strategies with your doctor. Always consult with your physician regarding any changes to your treatment plan or concerns about diuretic effectiveness.
The takeaway
The study suggests that at-home subcutaneous diuretic therapy is feasible for some heart failure patients. Continue tracking symptoms like daily weight and leg swelling, and be sure to discuss any new or worsening signs of fluid retention with your primary care team or cardiologist.
Further reading
For more on managing long-term heart health, visit Heart Disease.
More information
View the official Gator SCALES-WHF clinical trial information to learn more about the research parameters.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you prefer using home-based medical devices over traditional hospital visits for managing chronic conditions?
